Recent Finacing
Recent Raise
Vivace Therapeutics is a San Mateo–based small‑molecule discovery and development company targeting the Hippo‑YAP/TEAD pathway, developing TEAD autopalmitoylation inhibitors (VT3989), bispecific irreversible antibodies, and immuno‑oncology combinations.
